The immunobiology of mTOR in autoimmunity

Wang, 2015, Human autoimmune diseases: a comprehensive update, J. Intern. Med., 278, 369, 10.1111/joim.12395 Buckley, 2015, Stromal cells in chronic inflammation and tertiary lymphoid organ formation, Annu. Rev. Immunol., 33, 715, 10.1146/annurev-immunol-032713-120252 Crowley, 2018, The forgotten cells of innate immune memory, Clin. Exp. Immunol., 193, 24, 10.1111/cei.13149 Ganeshan, 2014, Metabolic regulation of immune responses, Annu. Rev. Immunol., 32, 609, 10.1146/annurev-immunol-032713-120236 Gaber, 2017, Metabolic regulation of inflammation, Nat. Rev. Rheumatol., 13, 267, 10.1038/nrrheum.2017.37 Linke, 2017, mTORC1 and mTORC2 as regulators of cell metabolism in immunity, FEBS Lett., 591, 3089, 10.1002/1873-3468.12711 Weichhart, 2015, Regulation of innate immune cell function by mTOR, Nat. Rev. Immunol., 15, 599, 10.1038/nri3901 Eng, 1984, Activity of rapamycin (AY-22,989) against transplanted tumors, J. Antibiot. (Tokyo), 37, 1231, 10.7164/antibiotics.37.1231 Martel, 1977, Inhibition of the immune response by rapamycin, a new antifungal antibiotic, Can. J. Physiol. Pharmacol., 55, 48, 10.1139/y77-007 Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin-receptor complex, Nature, 369, 756, 10.1038/369756a0 Sabatini, 1994, RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, 78, 35, 10.1016/0092-8674(94)90570-3 Sabers, 1995, Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells, J. Biol. Chem., 270, 815, 10.1074/jbc.270.2.815 Saxton, 2017, mTOR signaling in growth, metabolism, and disease, Cell, 168, 960, 10.1016/j.cell.2017.02.004 Mossmann, 2018, mTOR signalling and cellular metabolism are mutual determinants in cancer, Nat. Rev. Cancer, 18, 744, 10.1038/s41568-018-0074-8 McMahon, 2011, The evolving role of mTOR inhibition in transplantation tolerance, J. Am. Soc. Nephrol., 22, 408, 10.1681/ASN.2010040351 Perl, 2016, Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases, Nat. Rev. Rheumatol., 12, 169, 10.1038/nrrheum.2015.172 Kim, 2019, mTOR as a central hub of nutrient signalling and cell growth, Nat. Cell Biol., 21, 63, 10.1038/s41556-018-0205-1 Nojima, 2003, The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif, J. Biol. Chem., 278, 15461, 10.1074/jbc.C200665200 Schalm, 2003, TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function, Curr. Biol., 13, 797, 10.1016/S0960-9822(03)00329-4 Sancak, 2008, The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1, Science, 320, 1496, 10.1126/science.1157535 Yang, 2013, mTOR kinase structure, mechanism and regulation, Nature, 497, 217, 10.1038/nature12122 Peterson, 2009, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, Cell, 137, 873, 10.1016/j.cell.2009.03.046 Sancak, 2007, PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase, Mol. Cell, 25, 903, 10.1016/j.molcel.2007.03.003 Sabatini, 2017, Twenty-five years of mTOR: uncovering the link from nutrients to growth, Proc. Natl. Acad. Sci. U. S. A., 114, 11818, 10.1073/pnas.1716173114 Roberts, 2014, Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition, Mol. Cell, 53, 521, 10.1016/j.molcel.2013.12.019 Gwinn, 2008, AMPK phosphorylation of raptor mediates a metabolic checkpoint, Mol. Cell, 30, 214, 10.1016/j.molcel.2008.03.003 Brugarolas, 2004, Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex, Genes Dev., 18, 2893, 10.1101/gad.1256804 Wolfson, 2017, The dawn of the age of amino acid sensors for the mTORC1 pathway, Cell Metabol., 26, 301, 10.1016/j.cmet.2017.07.001 Wyant, 2017, mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient, Cell, 171, 642, 10.1016/j.cell.2017.09.046 Rebsamen, 2015, SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1, Nature, 519, 477, 10.1038/nature14107 Wang, 2015, Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1, Science, 347, 188, 10.1126/science.1257132 Wolfson, 2016, Sestrin2 is a leucine sensor for the mTORC1 pathway, Science, 351, 43, 10.1126/science.aab2674 Chantranupong, 2016, The CASTOR proteins are arginine sensors for the mTORC1 pathway, Cell, 165, 153, 10.1016/j.cell.2016.02.035 Sinclair, 2013, Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T-cell differentiation, Nat. Immunol., 14, 500, 10.1038/ni.2556 Nakaya, 2014, Inflammatory T-cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation, Immunity, 40, 692, 10.1016/j.immuni.2014.04.007 Kobayashi, 2014, The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production, Immunity, 41, 375, 10.1016/j.immuni.2014.08.011 Inoki, 2003, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling, Genes Dev., 17, 1829, 10.1101/gad.1110003 Tee, 2003, Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb, Curr. Biol., 13, 1259, 10.1016/S0960-9822(03)00506-2 Karonitsch, 2018, mTOR senses environmental cues to shape the fibroblast-like synoviocyte response to inflammation, Cell Rep., 23, 2157, 10.1016/j.celrep.2018.04.044 Zeng, 2018, Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells, J. Cell. Physiol., 233, 516, 10.1002/jcp.25913 Marcais, 2014, The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells, Nat. Immunol., 15, 749, 10.1038/ni.2936 Zhu, 2014, TSC1 controls macrophage polarization to prevent inflammatory disease, Nat. Commun., 5, 4696, 10.1038/ncomms5696 Weichhart, 2008, The TSC-mTOR signaling pathway regulates the innate inflammatory response, Immunity, 29, 565, 10.1016/j.immuni.2008.08.012 Katzman, 2010, Duration of antigen receptor signaling determines T-cell tolerance or activation, Proc. Natl. Acad. Sci. U. S. A., 107, 18085, 10.1073/pnas.1010560107 Colombetti, 2006, Prolonged TCR/CD28 engagement drives IL-2-independent T-cell clonal expansion through signaling mediated by the mammalian target of rapamycin, J. Immunol., 176, 2730, 10.4049/jimmunol.176.5.2730 Fruman, 2017, The PI3K pathway in human disease, Cell, 170, 605, 10.1016/j.cell.2017.07.029 Mendoza, 2011, The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation, Trends Biochem. Sci., 36, 320, 10.1016/j.tibs.2011.03.006 Katholnig, 2013, p38alpha senses environmental stress to control innate immune responses via mechanistic target of rapamycin, J. Immunol., 190, 1519, 10.4049/jimmunol.1202683 Covarrubias, 2016, Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation, Elife, 5, 10.7554/eLife.11612 Weintz, 2010, The phosphoproteome of toll-like receptor-activated macrophages, Mol. Syst. Biol., 6, 371, 10.1038/msb.2010.29 Lelouard, 2007, Regulation of translation is required for dendritic cell function and survival during activation, J. Cell Biol., 179, 1427, 10.1083/jcb.200707166 Holz, 2005, mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events, Cell, 123, 569, 10.1016/j.cell.2005.10.024 Ma, 2009, Molecular mechanisms of mTOR-mediated translational control, Nat. Rev. Mol. Cell Biol., 10, 307, 10.1038/nrm2672 Gingras, 1999, Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism, Genes Dev., 13, 1422, 10.1101/gad.13.11.1422 Brunn, 1997, Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin, Science, 277, 99, 10.1126/science.277.5322.99 Colina, 2008, Translational control of the innate immune response through IRF-7, Nature, 452, 323, 10.1038/nature06730 Ivanov, 2013, Pathogen signatures activate a ubiquitination pathway that modulates the function of the metabolic checkpoint kinase mTOR, Nat. Immunol., 14, 1219, 10.1038/ni.2740 Woodcock, 2019, The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis, Nat. Commun., 10, 6, 10.1038/s41467-018-07858-8 Porstmann, 2008, SREBP activity is regulated by mTORC1 and contributes to Akt-dependenT-cell growth, Cell Metabol., 8, 224, 10.1016/j.cmet.2008.07.007 Shimano, 2017, SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology, Nat. Rev. Endocrinol., 13, 710, 10.1038/nrendo.2017.91 Bakan, 2012, Connecting mTORC1 signaling to SREBP-1 activation, Curr. Opin. Lipidol., 23, 226, 10.1097/MOL.0b013e328352dd03 Lee, 2018, SREBP-1a-stimulated lipid synthesis is required for macrophage phagocytosis downstream of TLR4-directed mTORC1, Proc. Natl. Acad. Sci. U. S. A., 115, E12228, 10.1073/pnas.1813458115 Kidani, 2013, Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T-cells and adaptive immunity, Nat. Immunol., 14, 489, 10.1038/ni.2570 Hudson, 2002, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin, Mol. Cell. Biol., 22, 7004, 10.1128/MCB.22.20.7004-7014.2002 Duvel, 2010, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol. Cell, 39, 171, 10.1016/j.molcel.2010.06.022 Brugarolas, 2003, TSC2 regulates VEGF through mTOR-dependent and -independent pathways, Cancer Cell, 4, 147, 10.1016/S1535-6108(03)00187-9 Kim, 2006, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia, Cell Metabol., 3, 177, 10.1016/j.cmet.2006.02.002 Shi, 2011, HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells, J. Exp. Med., 208, 1367, 10.1084/jem.20110278 Corcoran, 2016, HIF1alpha and metabolic reprogramming in inflammation, J. Clin. Investig., 126, 3699, 10.1172/JCI84431 Salmond, 2018, mTOR regulation of glycolytic metabolism in T-cells, FronT-cell Dev Biol, 6, 122, 10.3389/fcell.2018.00122 Cheng, 2014, mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity, Science, 345, 1250684, 10.1126/science.1250684 Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr. Biol., 14, 1296, 10.1016/j.cub.2004.06.054 Jacinto, 2004, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nat. Cell Biol., 6, 1122, 10.1038/ncb1183 Pearce, 2007, Identification of Protor as a novel Rictor-binding component of mTOR complex-2, Biochem. J., 405, 513, 10.1042/BJ20070540 Frias, 2006, mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s, Curr. Biol., 16, 1865, 10.1016/j.cub.2006.08.001 Jacinto, 2006, SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity, Cell, 127, 125, 10.1016/j.cell.2006.08.033 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Zinzalla, 2011, Activation of mTORC2 by association with the ribosome, Cell, 144, 757, 10.1016/j.cell.2011.02.014 Byles, 2013, The TSC-mTOR pathway regulates macrophage polarization, Nat. Commun., 4, 2834, 10.1038/ncomms3834 Yang, 2015, A positive feedback loop between akt and mTORC2 via SIN1 phosphorylation, Cell Rep., 12, 937, 10.1016/j.celrep.2015.07.016 Phung, 2006, Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin, Cancer Cell, 10, 159, 10.1016/j.ccr.2006.07.003 Sarbassov, 2006, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB, Mol. Cell, 22, 159, 10.1016/j.molcel.2006.03.029 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Garcia-Martinez, 2008, mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochem. J., 416, 375, 10.1042/BJ20081668 Manning, 2017, AKT/PKB signaling: navigating the network, Cell, 169, 381, 10.1016/j.cell.2017.04.001 Guertin, 2006, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1, Dev. Cell, 11, 859, 10.1016/j.devcel.2006.10.007 Brown, 2011, Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1, J. Biol. Chem., 286, 44295, 10.1074/jbc.M111.258053 Huang, 2016, Metabolic reprogramming mediated by the mTORC2-IRF4 signaling Axis is essential for macrophage alternative activation, Immunity, 45, 817, 10.1016/j.immuni.2016.09.016 Oh, 2017, mTORC2 signaling selectively regulates the generation and function of tissue-resident peritoneal macrophages, Cell Rep., 20, 2439, 10.1016/j.celrep.2017.08.046 Pollizzi, 2015, mTORC1 and mTORC2 selectively regulate CD8(+) T-cell differentiation, J. Clin. Investig., 125, 2090, 10.1172/JCI77746 Zhang, 2016, Mammalian target of rapamycin complex 2 controls CD8 T-cell memory differentiation in a foxo1-dependent manner, Cell Rep., 14, 1206, 10.1016/j.celrep.2015.12.095 Lee, 2010, Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways, Immunity, 32, 743, 10.1016/j.immuni.2010.06.002 Heikamp, 2014, The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex, Nat. Immunol., 15, 457, 10.1038/ni.2867 Wu, 2018, SGK1 governs the reciprocal development of Th17 and regulatory T-cells, Cell Rep., 22, 653, 10.1016/j.celrep.2017.12.068 Liu, 2010, mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion, Dev. Cell, 19, 845, 10.1016/j.devcel.2010.11.004 Fernandez, 2009, Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T-cells through HRES-1/Rab4-regulated lysosomal degradation, J. Immunol., 182, 2063, 10.4049/jimmunol.0803600 Blokland, 2019, Increased mTORC1 activation in salivary gland B-cells and T-cells from patients with Sjogren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?, RMD Open, 5, 10.1136/rmdopen-2018-000701 Mitra, 2015, Dual mTOR inhibition is required to prevent TGF-beta-mediated fibrosis: implications for scleroderma, J. Investig. Dermatol., 135, 2873, 10.1038/jid.2015.252 Tsokos, 2016, New insights into the immunopathogenesis of systemic lupus erythematosus, Nat. Rev. Rheumatol., 12, 716, 10.1038/nrrheum.2016.186 Oaks, 2016, Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice, Arthritis Rheum., 68, 2728, 10.1002/art.39791 Lui, 2008, Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice, Nephrol. Dial. Transplant., 23, 2768, 10.1093/ndt/gfn216 Warner, 1994, Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus, Arthritis Rheum., 37, 289, 10.1002/art.1780370219 Lai, 2018, Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial, Lancet, 391, 1186, 10.1016/S0140-6736(18)30485-9 Yap, 2018, Longterm data on sirolimus treatment in patients with lupus nephritis, J. Rheumatol., 45, 1663, 10.3899/jrheum.180507 Lai, 2013, Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T-cells in patients with systemic lupus erythematosus, J. Immunol., 191, 2236, 10.4049/jimmunol.1301005 Kato, 2014, Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T-cells and contracts regulatory T-cells in systemic lupus erythematosus, J. Immunol., 192, 4134, 10.4049/jimmunol.1301859 Bonelli, 2010, Treg and lupus, Ann. Rheum. Dis., 69, i65, 10.1136/ard.2009.117135 Huang, 2015, Predominant role of plasmacytoid dendritic cells in stimulating systemic autoimmunity, Front. Immunol., 6, 526, 10.3389/fimmu.2015.00526 Smolen, 2016, Rheumatoid arthritis, Lancet, 388, 2023, 10.1016/S0140-6736(16)30173-8 Kiener, 2011, The synovium as a privileged site in rheumatoid arthritis: cadherin-11 as a dominant player in synovial pathology, Best Pract. Res. Clin. Rheumatol., 25, 767, 10.1016/j.berh.2011.11.012 Kubota, 2011, FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT, Ann. N. Y. Acad. Sci., 1228, 29, 10.1111/j.1749-6632.2011.06031.x Kim, 2014, Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis, PLoS One, 9 Carlson, 2019, Characterization of synovial fluid metabolomic phenotypes of cartilage morphological changes associated with osteoarthritis, Osteoarthr. Cartil., 27, 1174, 10.1016/j.joca.2019.04.007 Bruyn, 2008, Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study, Ann. Rheum. Dis., 67, 1090, 10.1136/ard.2007.078808 Saxena, 2011, Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent, Arthritis Rheum., 63, 1465, 10.1002/art.30278 Laragione, 2010, mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis, Mol. Med., 16, 352, 10.2119/molmed.2010.00049 Brandstetter, 2019, FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes, Lab. Investig., 99, 648, 10.1038/s41374-018-0184-7 Cejka, 2010, Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis, Arthritis Rheum., 62, 2294, 10.1002/art.27504 Niu, 2019, Sirolimus selectively increases circulating Treg cell numbers and restores the Th17/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic drugs, Clin. Exp. Rheumatol. Pallet, 2013, Adverse events associated with mTOR inhibitors, Expert Opin. Drug Saf., 12, 177, 10.1517/14740338.2013.752814 Denton, 2017, Systemic sclerosis, Lancet, 390, 1685, 10.1016/S0140-6736(17)30933-9 Yoshizaki, 2010, Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis, Arthritis Rheum., 62, 2476, 10.1002/art.27498 Zhu, 2017, Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway, J. Dermatol. Sci., 87, 149, 10.1016/j.jdermsci.2017.04.013 Rahimi, 2009, Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta, Cancer Res., 69, 84, 10.1158/0008-5472.CAN-08-2146 Su, 2009, Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study, Arthritis Rheum., 60, 3821, 10.1002/art.24986 Mariette, 2018, Primary sjogren's syndrome, N. Engl. J. Med., 379, 97 Shah, 2013, A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren's syndrome, J. Control. Release, 171, 269, 10.1016/j.jconrel.2013.07.016 Taams, 2018, IL-17 in the immunopathogenesis of spondyloarthritis, Nat. Rev. Rheumatol., 14, 453, 10.1038/s41584-018-0044-2 Xu, 2015, Up-regulation of fatty acid oxidation in the ligament as a contributing factor of ankylosing spondylitis: a comparative proteomic study, J Proteomics, 113, 57, 10.1016/j.jprot.2014.09.014 Kurebayashi, 2012, PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma, Cell Rep., 1, 360, 10.1016/j.celrep.2012.02.007